Vimarsana
Biggest News Aggregation in the World

Interference Observed News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Interference Observed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Interference Observed Today - Breaking & Trending Today

DGAP-News: Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update - Vimarsana News

DGAP-News: Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update

Published: June 2, 2022

Issuer: Immunic, Inc. / Key word(s): Study results Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis

Source: finanznachrichten.de
Related Topics:
United StatesPaula SchwartzEdna KaplanJessica BreuAndreas MuehlerDaniel VittFund ImmunicDevelopment Of Vidofludimus Calcium In Multiple SclerosisRx Communications GroupDistribution ServicesExchange CommissionImmunic IncReports Top Line DataVidofludimus CalciumModerate To Severe Ulcerative ColitisProvides Corporate UpdateProvides CorporateDid Not Achieve Primary EndpointUlcerative ColitisPopulation CausedConcurrent UseWithout Concurrent Steroid UsePooled Vidofludimus Calcium Data Suggest ActivityClinical Remission Over PlaceboInterference Observed
Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update - Vimarsana News

Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update

Published: June 2, 2022

– Trial Did Not Achieve Primary Endpoint in the Ulcerative Colitis (UC) Population Caused by Unexpected Interference Between Vidofludimus Calcium and...

Source: prnewswire.com
Related Topics:
United StatesPaula SchwartzEdna KaplanJessica BreuAndreas MuehlerDaniel VittExchange CommissionFund ImmunicDevelopment Of Vidofludimus Calcium In Multiple SclerosisRx Communications GroupImmunic IncTrial Did Not Achieve Primary EndpointUlcerative ColitisPopulation CausedConcurrent UseWithout Concurrent Steroid UsePooled Vidofludimus Calcium Data Suggest ActivityClinical Remission Over PlaceboInterference ObservedConcurrent Steroid UseUlcerative Colitis WithoutOngoing PhaseVidofludimus CalciumMultiple SclerosisClinical Data